申请人:PharmatrophiX, Inc.
公开号:US20160229823A1
公开(公告)日:2016-08-11
The present application is related to deuterated compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders involving degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such deuterated compounds.
本申请涉及新型神经营养因子类似物的氘代化合物。该申请还揭示了通过给哺乳动物以有效量的这种氘代化合物来治疗涉及表达p75的细胞降解或功能障碍的疾病。